In Alzheimer’s disease (AD), MCL mitigates neuroinflammation by inhibiting the NF-κB and PI3K/Akt pathways in glial cells, leading to a reduction in inflammatory mediators and improvements in cognitive function, positioning MCL as a promising therapeutic candidate for AD (Yang G. et al., 2023). The gene discussed is AKT1; the disease is Alzheimer disease.